Valuation: Zai Lab Limited

Market Cap 2.05B 1.78B 1.65B 1.52B 2.87B 195B 2.92B 19.54B 7.65B 97.01B 7.68B 7.52B 326B P/E 2026 *
-8.12x
P/E 2027 * -9.69x
Enterprise Value 1.55B 1.35B 1.25B 1.15B 2.18B 148B 2.21B 14.83B 5.8B 73.61B 5.83B 5.7B 248B EV / Sales 2026 *
3.47x
EV / Sales 2027 * 2.82x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 week-8.67%
Current month-4.82%
1 month-4.82%
3 months-14.13%
6 months+12.86%
Current year+6.76%
1 week 15.5
Extreme 15.5
17.2
1 month 15.5
Extreme 15.5
18.2
3 years 12.6
Extreme 12.6
38.2
5 years 12.6
Extreme 12.6
130
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%-10.61%-52.41%-45.89% 2.05B
-0.33%+13.26%+33.13%-1.04% 75.12B
+3.82%-8.33%+18.40%+180.05% 47.63B
+3.25%+52.70%+52.70%+52.70% 49.48B
-3.81%+6.32%-54.61%-54.17% 42.95B
-0.50%+3.64%+64.19%-21.60% 30.72B
-2.89%+5.40%+58.59%+94.94% 24.93B
-0.51%+1.58%+80.16%-51.19% 22.98B
-1.59%-3.61%-11.53%+150.58% 19.56B
+0.49%+4.68%+77.60%+132.43% 17.19B
Average -0.28%+3.10%+26.62%+43.68% 36.73B
Weighted average by Cap. +0.08%+3.99%+29.78%+43.39%

Financials

2026 *2027 *
Net sales 448M 389M 361M 333M 627M 42.74B 639M 4.27B 1.67B 21.22B 1.68B 1.64B 71.38B 595M 516M 480M 442M 833M 56.77B 848M 5.68B 2.22B 28.19B 2.23B 2.18B 94.81B
Net income -244M -212M -197M -182M -342M -23.31B -348M -2.33B -913M -11.58B -917M -897M -38.93B -159M -138M -128M -118M -223M -15.17B -227M -1.52B -594M -7.53B -597M -583M -25.33B
Net Debt -493M -429M -398M -367M -691M -47.11B -704M -4.71B -1.85B -23.4B -1.85B -1.81B -78.69B -371M -323M -300M -276M -520M -35.46B -530M -3.55B -1.39B -17.61B -1.39B -1.36B -59.22B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
31/07/26 15.80 0.00%
30/07/26 €15.80 -1.25%
29/07/26 €16.00 -1.84%
28/07/26 €16.30 -0.61%
27/07/26 €16.40 -2.96%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.21USD
Average target price
33.30USD
Spread / Average Target
+82.88%

Quarterly revenue - Rate of surprise